A cell-permeable p53 inhibitor
p-nitro-pifithrin-α, a cell-permeable cyclic analog of pifithrin-α, is an inhibitor of p53 activity [1].the p53 tumor suppressor gene product can induce apoptotic cell death and plays a dominant role in apoptosis, genomic stability, and inhibition of angiogenesis. the p53 has been considered to be an oncogene and the wild-type gene product actually functions as a tumour suppressor gene. p53 mutations play an important role in the development of many common human malignancies [2].in human proximal tubular cells, p-nitro-pifithrin-α (10 μm) suppressed p53-mediated tgf-β1 expression [3].
in p53-/- cortical neuron, p-nitro-pifithrin-α exihibited a p53 inhibitory activity in preventing p53-induced death[1]. p-nitro-pifithrin-α did not prevent cortical neuronal death induced by p40met, showing the remarkable specificity in the inhibitory action of p-nitro-pifithrin-α on p53. p-nitro-pifithrin-α (300 nm) prevented p53-triggered increase in protein levels of p21/waf1, indicating that p-nitro-pifithrin-α behaved as p53 posttranscriptional activity inhibitors. p-nitro-pifithrin-α at a dose of 30 nm was sufficient to prevent the increase of p21/waf1 levels [1]. p-nitro-pifithrin-α was slowly converted into a more potent cyclized form, p-nitro cyclic pifithrin-α, when incubated in biological media (t1/2= 8 h)
in a mouse model of non-alcoholic fatty liver disease, p-nitro-pifithrin-α attenuated steatosis and liver injury in mice fed a high-fat diet [4].
[1] pietrancosta n, moumen a, dono r, et al. imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism[j]. journal of medicinal chemistry, 2006, 49(12): 3645-3652.
[2] nigro j m, baker s j, preisinger a c, et al. mutations in the p53 gene occur in diverse human tumour types[j]. nature, 1989, 342(6250): 705-708.
[3] shimizu h, yisireyili m, nishijima f, et al. indoxyl sulfate enhances p53-tgf-β1-smad3 pathway in proximal tubular cells[j]. american journal of nephrology, 2013, 37(2): 97-103.
[4] derdak z, villegas k a, harb r, et al. inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease[j]. journal of hepatology, 2013, 58(4): 785-791.
